Daily Newsletter

05 March 2024

Daily Newsletter

05 March 2024

A2 Bio’s cell therapy gains FDA orphan drug status for colorectal cancer

The designation brings development incentives for A2 Bio, including tax credits for clinical trial costs.

Vishnu Priyan March 05 2024

A2 Biotherapeutics (A2 Bio) has received the US Food and Drug Administration's (FDA) orphan drug designation for its cell therapy, A2B530, to treat colorectal cancer.

The designation is a significant milestone for A2B530, the first autologous logic-gated therapy developed from A2 Bio's Tmod platform.

The cell therapy is aimed at treating germline heterozygous HLA-A*02(+) patients who express carcinoembryonic antigen (CEA) and have lost HLA-A*02 expression.

The Tmod platform's dual-receptor design, comprising an activator that targets tumour cells and a blocker for normal cells, addresses the issue with other solid tumour cancer treatments. It acts by selectively targeting tumour cells while sparing healthy ones.

A2B530 deploys an activator for CEA and a blocker for HLA-A*02, potentially offering a more precise cancer treatment approach.

Orphan drug status brings development incentives for A2 Bio, including tax credits for clinical trial costs, prescription drug user fee exemptions and the possibility of up to seven years of market exclusivity upon regulatory approval.

In May 2023, the company dosed the first subject in the Phase I clinical trial of A2B530.

The multicentre Phase I dose escalation trial EVEREST-1 enrolled patients with colorectal, pancreatic and non-small cell lung cancers to assess safety and establish the recommended dose for A2B530.

A2 Bio chief medical officer William Go stated: “The FDA granting orphan drug designation validates the tremendous unmet need for improved therapies for patients with colorectal cancer.

“This designation supports our commitment to use our novel technology platform to develop new treatment options for patients with difficult-to-treat cancers.”

In December 2020, the company signed an agreement with MSD to continue research and preclinical development of its undisclosed Tmod cell therapy candidate.

The companies jointly financed the clinical development and allogeneic manufacturing works of the product until the start of the Phase I clinical trial.

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close